Anti-PD1 therapies induce an early expansion of Ki67+CD8+ T cells in metastatic non-oncogene addicted NSCLC patients

Pembrolizumab (an anti-PD1 antibody) alone or combined with chemotherapy represented the standard of care for advanced non-oncogene addicted non-small cell lung cancer (NSCLC) patients. These therapies induced early modifications of the immune response impacting the clinical outcome. Identifying ear...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Alain Gelibter, Lucrezia Tuosto, Angela Asquino, Marco Siringo, Arianna Sabatini, Ilaria Grazia Zizzari, Angelica Pace, Fabio Scirocchi, Flavio Valentino, Serena Bianchini, Salvatore Caponnetto, Donatella Paoli, Filippo Bellati, Daniele Santini, Marianna Nuti, Aurelia Rughetti, Chiara Napoletano
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Frontiers Media S.A. 2024-12-01
Schriftenreihe:	Frontiers in Immunology
Schlagworte:	NSCLC immune checkpoint inhibitors anti-PD-1 lymphocytes CD137
Online-Zugang:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1483182/full
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!